MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Company business development and clinical team members will attend the event scheduled for January 8–10, 2026 at the Chateaux Deer Valley in Park City, Utah.

This participation highlights MetaVia's engagement with the cardiometabolic and clinical research community but does not include financial or clinical readouts in this announcement.

News Market Reaction – MTVA

-2.07%

1 alert

-2.07% Session close to close

$20.70M Market Cap

0.1x Rel. Volume

In the Dec 29 session, MTVA declined 2.07%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights MetaVia’s continued engagement with the MASH community and cardiometabo...

Analysis

This announcement highlights MetaVia’s continued engagement with the MASH community and cardiometabolic stakeholders through the 10th Annual MASH-TAG 2026 Conference on January 8–10, 2026. In recent months, the company paired positive data for vanoglipel and DA-1726 with significant capital-structure steps, including a 1-for-11 reverse split and an at-the-market offering of up to $2.3M. Investors may watch for further clinical updates, funding developments, and Nasdaq listing status as key markers of future progress.

Key Figures

Conference edition: 10th Annual Conference dates: January 8–10, 2026

2 metrics

Conference edition 10th Annual MASH-TAG 2026 conference

Conference dates January 8–10, 2026 MASH-TAG 2026 in Park City, Utah

Historical Context

5 past events · Latest: Dec 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 22	Listing compliance	Positive	+11.6%	Regained compliance with Nasdaq minimum bid requirement and closed related matter.
Dec 02	Reverse stock split	Negative	-20.1%	1-for-11 reverse split to address Nasdaq listing requirements and adjust share count.
Nov 07	Phase 2a data	Positive	+6.8%	Positive Phase 2a results for vanoglipel in presumed MASH with metabolic benefits.
Nov 06	Q3 earnings update	Negative	-15.0%	Q3 2025 results with going-concern language despite pipeline and cash update.
Nov 04	Conference data	Positive	+8.0%	New Phase 1 and preclinical data on DA-1726 presented at ObesityWeek 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has consistently seen price moves that align with the underlying news tone, both positive clinical updates and financing/listing actions.

Recent Company History

Over the past few months, MetaVia has combined clinical progress with capital-structure moves. Positive data for vanoglipel and DA-1726 in late 2025 coincided with notable price gains, while the 1-for-11 reverse split on Dec 4, 2025 and going-concern language in Q3 2025 results were followed by declines. Regaining Nasdaq minimum bid compliance on Dec 19, 2025 saw a positive reaction. Today’s conference participation fits the pattern of ongoing visibility efforts alongside earlier clinical milestones and financing activities.

Key Terms

cardiometabolic

1 terms

cardiometabolic medical

"a clinical-stage biotechnology company focused on transforming cardiometabolic diseases"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate in and sponsor the 10^th Annual MASH-TAG 2026 Conference. Members of MetaVia's business development and clinical teams will attend the conference, which will take place January 8-10 at the Chateaux Deer Valley in Park City, Utah.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-participate-in-and-sponsor-the-10th-annual-mash-tag-2026-conference-302649854.html

SOURCE MetaVia Inc.

FAQ

When will MetaVia (MTVA) attend the 10th Annual MASH-TAG 2026 Conference?

MetaVia will attend and sponsor the conference on January 8–10, 2026.

Where is the MASH-TAG 2026 Conference that MetaVia (MTVA) is sponsoring?

The conference takes place at the Chateaux Deer Valley, Park City, Utah.

Which MetaVia teams will be present at MASH-TAG 2026 for MTVA?

Members of MetaVia's business development and clinical teams will attend.

Does MetaVia (MTVA) announce any clinical data or financial guidance at MASH-TAG 2026?

This announcement does not include any clinical readouts or financial guidance.

How can investors follow MetaVia (MTVA) participation at MASH-TAG 2026?

Investors should monitor MetaVia investor relations channels for any presentation or webcast details following the event.